Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows in line with its trailing trend
Q2 FY2026 stock-based compensation of $170.2M rose 1.7% year over year, ahead of the +0.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Stock-based compensation amounted to 5.7% of revenue in FY2025, down 0.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of +0.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 685.9M USD
- Year-over-year change
- -1.8%
- 4-year CAGR
- +11.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 685.9M | -1.8% |
| FY2024 | 2024-12-31 | 698.5M | +20.2% |
| FY2023 | 2023-12-31 | 581.2M | +18.3% |
| FY2022 | 2022-12-31 | 491.3M | +11.3% |
| FY2021 | 2021-12-31 | 441.4M | — |
Stock-Based Compensation vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Jun 2026 stock-based compensation of $689.1M is the 2nd largest of the 11 companies compared; the peer median is $122.12M.
- Its year-over-year change of +0.5% is the 6th highest of 11, against a peer median of -2.1%.
- Stock-based compensation amounts to 5.5% of revenue for VRTX, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $172.73B | +92559.3% | -2.6% | 16.8% | |
| LTM Jun 2026 | $689.1M | +0.5% | +11.8% | 5.5% | |
| LTM Jun 2026 | $336.62M | +10.1% | +14.7% | 7.0% | |
| LTM Mar 2026 | $145.91M | +2.8% | +19.1% | 220.8% | |
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Jun 2026 | $111.95M | -7.0% | +13.3% | 15.7% | |
| LTM Mar 2026 | $111.37M | -39.8% | -19.1% | 5.1% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Sep 2026 | $69.68M | -8.8% | -9.5% | 276.8% | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| Peer median (excluding VRTX) | $122.12M | -2.1% | +4.6% | 14.7% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| Deferred Income Tax | (154.6M) | (275.9M) | (536.5M) | (348.8M) | (510.8M) |
| Stock-Based Compensation | 441.4M | 491.3M | 581.2M | 698.5M | 685.9M |
| Change in Working Capital | (105.2M) | 340.8M | (265.7M) | (514.8M) | (1.2B) |
| Accounts Receivables | (274.7M) | (358.6M) | (84.1M) | (99.3M) | (347.3M) |
| Inventory | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (524.2M) |
| Accounts Payables | 31.9M | 120.8M | 48.7M | 49.5M | 36.8M |
| Other Working Capital | 230.4M | 715M | 92.6M | 52.3M | (364.4M) |
| Other Non-Cash Items | (5.8M) | 103.4M | (42.6M) | 900K | 492.4M |
| Operating Cash Flow | 2.64B | 4.13B | 3.54B | (492.6M) | 3.63B |
| Capital Expenditures | (235M) | (204.7M) | (258.4M) | (297.7M) | (437.6M) |
| Acquisitions (Net) | 77M | (295.9M) | 0 | 0 | 0 |
| Purchases of Investments | (605.2M) | (692.7M) | (3.79B) | (7.7B) | (6.4B) |
| Sales of Investments | 499.3M | 920M | 934.2M | 4.47B | 5.91B |
| Other Investing Activities | (77M) | (47.8M) | (89M) | (241.7M) | (24.7M) |
| Investing Cash Flow | (340.9M) | (321.1M) | (3.14B) | (3.77B) | (945.4M) |
| Debt Repayment | (18.7M) | (85.5M) | (44.9M) | (33.6M) | (5.4M) |
| Common Stock Issued | 102M | 186.3M | 134.6M | 114.6M | 127.7M |
| Common Stock Repurchased | (1.43B) | (172M) | (427.6M) | (1.18B) | (2.02B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (130.2M) | 3.5M | (224.3M) | (398.8M) | (366.2M) |
| Financing Cash Flow | (1.48B) | (67.7M) | (562.2M) | (1.49B) | (2.26B) |
| Effect of Forex Changes | (13.4M) | (29.2M) | 26.9M | (42.6M) | 90.9M |
| Net Change in Cash | 811.2M | 3.71B | (139.7M) | (5.8B) | 515.6M |
| Free Cash Flow | 2.41B | 3.93B | 3.28B | (790.3M) | 3.19B |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.